Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.64 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.64 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 9/20 | 0.35 |
| ▸ | CRY1 | Q16526 | 8/20 | 0.35 |
| ▸ | PER2 | O15055 | 7/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873314 | 0.82 | OPRM1 (0.45) | OPRM1OPRL1OPRK1DRD2SLC6A4 | |
| SCHEMBL14280687 | 0.78 | OPRM1 (1.00) | OPRM1OPRL1OPRK1DRD2SLC6A4 | |
| SCHEMBL4880602 | 0.74 | OPRM1 (0.75) | OPRM1OPRL1OPRK1DRD2SLC6A4 | |
| SCHEMBL14280693 | 0.74 | OPRL1 (1.00) | OPRM1OPRL1OPRK1DRD2SLC6A4 | |
| SCHEMBL14280678 | 0.68 | OPRM1 (0.44) | OPRM1OPRL1OPRK1DRD2HRH2 | |
| SCHEMBL1383111 | 0.67 | OPRL1 (0.48) | OPRM1OPRL1OPRK1 | |
| SCHEMBL1383110 | 0.67 | OPRL1 (0.48) | OPRM1OPRL1OPRK1 | |
| SCHEMBL1383116 | 0.67 | OPRL1 (0.48) | OPRM1OPRL1OPRK1 | |
| SCHEMBL4873307 | 0.65 | OPRM1 (0.51) | OPRM1OPRL1OPRK1DRD2SLC6A4 | |
| SCHEMBL4062260 | 0.65 | HRH2 (0.57) | OPRM1OPRL1OPRK1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | OPRM1 11/4885OPRL1 2/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.